News
DYN
24.98
-1.81%
-0.46
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 1d ago
Weekly Report: what happened at DYN last week (0415-0419)?
Weekly Report · 3d ago
Notable Friday Option Activity: COIN, SIBN, DYN
NASDAQ · 5d ago
Weekly Report: what happened at DYN last week (0408-0412)?
Weekly Report · 04/15 09:02
Weekly Report: what happened at DYN last week (0401-0405)?
Weekly Report · 04/08 09:02
DYNE THERAPEUTICS INC <DYN.O>: JEFFERIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $36
Reuters · 04/08 05:38
Weekly Report: what happened at DYN last week (0325-0329)?
Weekly Report · 04/01 09:02
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
Dyne Therapeutics, Inc. Granted an inducement equity award to its newly appointed President and Chief Executive Officer, John G. Cox. The award was approved by the Compensation Committee of Dyne. Dyne is a clinical-stage muscle disease company focused on advancing innovative therapeutics.
Barchart · 03/27 15:05
Dyne Therapeutics Price Target Maintained With a $47.00/Share by Oppenheimer
Dow Jones · 03/26 14:18
Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $47 Price Target
Benzinga · 03/26 14:07
Analysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)
TipRanks · 03/26 12:00
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Landos Biopharma, Inc. Shares jumped 171.2% to $21.70 on Monday. AbbVie and Landos signed a definitive agreement to acquire the company. Altamira Therapeutics Ltd. Shares climbed 70.1% after falling around 22% on Friday. GameStop Corp. Shares rose 8.4% after the company announced a separation.
Benzinga · 03/25 18:44
BUZZ-U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
Dow Jones Industrial Average was down 0.36% on Monday. Top three S&P 500 percentage gainers: Super Micro Computer, Micron Technology, Navios Maritime. Wall Street's main indexes eased at the start of the holiday-shortened week. Advancing chip stocks kept losses on the tech-heavy Nasdaq in check.
Reuters · 03/25 17:56
BUZZ-U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Wall Street's main indexes open lower on Monday. Dow Jones Industrial Average was down 0.26% at 39,373.11. Boeing gained after the planemaker said its CEO would be stepping down. Landos Biopharma, Foot Locker, US energy sector rise.
Reuters · 03/25 15:58
Dyne Therapeutics Shares Drop 14% on CEO Joshua Brumm Departure
Shares of Dyne Therapeutics are down 14% to $24.22. The stock has surged 97% in the past three months. The company says CEO Joshua Brumm is leaving to pursue a career as a healthcare investor. Brumm will be succeeded by John Cox, a former Biogen executive.
Dow Jones · 03/25 14:36
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Shares of Aehr Test System tumbled 18.1% to $12.01 on Monday. The company reported preliminary third-quarter and FY24 results below estimates. The Dow Jones index fell around 100 points in today's session. Vimeo, Canopy Growth Corporation and United Airlines also recorded losses.
Benzinga · 03/25 14:32
BUZZ-Dyne slides after appointing new CEO
Shares of Dyne Therapeutics fall 11.5% to $25 premarket. Dyne appoints John Cox as CEO. Stock has more than doubled in the last 12 months. Shares of muscle disease specialist doubled in January after drug showed promise in early-stage trial.
Reuters · 03/25 12:59
Dyne Therapeutics appoints John Cox CEO
Healthcare Dyne Therapeutics appoints John Cox CEO. Cox succeeds Joshua Brumm, who is stepping down from these roles to pursue a career in healthcare investing. Cox, most recently, served as CEO at Repertoire Immune Medicines. Muscle disease company DyneTherapeutics, Inc.
Seeking Alpha · 03/25 11:54
Dyne Therapeutics Welcomes John Cox as New CEO and Board Member
TipRanks · 03/25 11:52
Dyne Therapeutics CEO Joshua Brumm to Exit For Investing Career
Joshua Brumm will leave Dyne Therapeutics to pursue a career as a healthcare investor. Dyne has named John Cox, a former Biogen executive, as its next CEO. Brumm was CEO of the clinical-stage muscle disease company since 2019. Cox says he was drawn to Dyne by recent clinical data.
Dow Jones · 03/25 11:46
More
Webull provides a variety of real-time DYN stock news. You can receive the latest news about Dyne Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About DYN
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.